<DOC>
	<DOCNO>NCT02089854</DOCNO>
	<brief_summary>The study prospective multi-center randomize control clinical trial sponsor researcher . The purpose study determine effectiveness adjuvant endocrine therapy operable ER-beta positive , ER-alpha/PR negative , Her-2 negative breast cancer ( triple negative breast cancer , TNBC ) patient . The ER-beta positive TNBC patient undergone modify radical mastectomy breast-conserving surgery randomly ( 1:1 ) enrol receive toremifene ( 60 mg per day premenopausal perimenopausal patient ) /anastrozole ( 1mg per day postmenopausal patient ) observation within 4 week adjuvant chemotherapy and/or radiation therapy necessary.The follow-up time least five year . The disease free survival ( DFS ) overall survival ( OS ) endocrine group observation group compare evaluate effectiveness .</brief_summary>
	<brief_title>Adjuvant Endocrine Therapy Estrogen Receptor-beta Positive Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>The patient sign write informed consent . The patient present histologically proven operable invasive breast cancer without distant metastasis . The breast tumor 's positive ER/PR rate &lt; 1 % , positive ERbeta rate ≥1 % immunohistochemistry ( IHC ) . The patient history neoadjuvant hormone therapy . The patient ' Karnofsky performance score ≥70 % . Female patient ≥ 18yrs , ≤ 80yrs . The patient nonpregnant , disposed practice contraception whole trial . The patient underwent neoadjuvant chemotherapy plus surgery directly modify radical mastectomy breastconserving surgery ( plus sentinel lymph node biopsy axillary lymph node dissection ) diagnosis breast cancer . The patient underwent chemotherapy , radiation therapy surgery accord 2013 NCCN guideline . The result patient ' blood test follow : Hb≥90g/L ; WBC≥4.0×109/L ; Neutrophils≥1.5×109/L ; Plt≥100×109/L ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 × upper limit normal ( ULN ) ; total bilirubin ( TBIL ) ≤ 1.5×ULN ; Creatinine ≤ 1.25×ULN . The patient previous history invasive malignant disease ( breast cancer time , malignant disorder within past 10 year exclude squamous basalcell carcinoma skin carcinoma situ cervix , adequately cone biopsied ) . The patient severe concomitant disease place patient unusual risk confound result trial . The patient history neoadjuvant hormone therapy . The patient undergoing current administration anticancer therapy , attend clinical trial . The patient pregnant lactational , refuse practice contraception whole trial . The patient unwilling stop hormonal drug include hormone replacement therapy ( HRT ) . The patient ca n't understand write informed consent ; dementia . The patient allergic history contraindication toremifene/anastrozole .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>estrogen receptor-beta</keyword>
	<keyword>endocrine therapy</keyword>
</DOC>